^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    Apply
    Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ (NCT06846463)
    Phase 2
    Virginia Commonwealth University
    Not yet recruiting
    Last update posted :
    02/26/2025
    Initiation :
    06/30/2025
    Primary completion :
    07/31/2029
    Completion :
    07/31/2032
    BCL2 • NOTCH1 • MYD88 • CD79B • CD5
    |
    doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib)
    Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (NCT00792948)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/01/2009
    Primary completion :
    06/01/2016
    Completion :
    01/06/2026
    ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (NCT03922724)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/18/2019
    Primary completion :
    06/30/2025
    Completion :
    06/30/2029
    ALK • HLA-B • HLA-C
    |
    ALK positive
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus
    Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (S2206) (NCT06058377)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/27/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2026
    HER-2 • ER • PGR
    |
    HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (NCT04119024)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/27/2019
    Primary completion :
    10/01/2025
    Completion :
    10/01/2026
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (NCT01861106)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/24/2013
    Primary completion :
    12/31/2027
    Completion :
    12/31/2028
    GATA2
    |
    GATA2 mutation
    |
    cyclophosphamide • fludarabine IV • busulfan • cyclophosphamide intravenous
    QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (NCT03169790)
    Phase 1/2
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/24/2025
    Initiation :
    12/01/2017
    Primary completion :
    01/01/2019
    Completion :
    12/23/2021
    CD20
    |
    CD20 positive
    |
    Avastin (bevacizumab) • Rituxan (rituximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-061 • NK92-CD16-158V • cyclophosphamide intravenous
    CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) (NCT04318678)
    Phase 1
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/29/2020
    Primary completion :
    05/01/2025
    Completion :
    05/01/2026
    CD123 • IL3RA
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy • cyclophosphamide intravenous
    NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors (NCT01875601)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    06/11/2013
    Primary completion :
    09/08/2015
    Completion :
    09/08/2015
    CD4
    |
    cyclophosphamide • rhIL-15
    Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (NCT04243616)
    Phase 2
    Medical College of Wisconsin
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/05/2020
    Primary completion :
    07/14/2025
    Completion :
    08/13/2025
    HER-2 • PD-L1 • PGR • PD-L2
    |
    PD-L1 expression • HER-2 negative • PGR positive
    |
    carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal
    Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (SWOG S1608) (NCT03269669)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/23/2018
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    CD4
    |
    lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • bendamustine • Ukoniq (umbralisib) • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous
    Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (NCT02905188)
    Phase 1
    Baylor College of Medicine
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    03/28/2019
    Primary completion :
    11/17/2021
    Completion :
    01/06/2023
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GLYCAR T cells • cyclophosphamide intravenous
    Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease (NCT06023641)
    Phase 1/2
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/13/2024
    Primary completion :
    10/01/2034
    Completion :
    10/01/2037
    TP53 • FOXO1 • MYOD1
    |
    TP53 mutation
    |
    temozolomide • cyclophosphamide • vincristine • vinorelbine tartrate • dactinomycin • Onivyde (nanoliposomal irinotecan) • Navelbine oral (vinorelbine tartrate oral) • Neupogen (filgrastim)
    Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (19-C-0116) (NCT04002947)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/05/2019
    Primary completion :
    05/31/2026
    Completion :
    03/31/2030
    ALK • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (NCT03554109)
    Phase 2
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/21/2025
    Initiation :
    09/01/2018
    Primary completion :
    06/01/2020
    Completion :
    02/09/2022
    HER-2 • ER • PGR
    |
    HER-2 overexpression • HER-2 amplification
    |
    5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
    Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (AALL1131) (NCT02883049)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    02/29/2012
    Primary completion :
    12/31/2022
    Completion :
    10/03/2025
    ABL1 • BCR • RUNX1 • KMT2A • ETV6
    |
    MLL rearrangement
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations (NCT06043713)
    Phase 1
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/15/2023
    Primary completion :
    12/31/2025
    Completion :
    02/09/2026
    HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK
    |
    KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion
    |
    cyclophosphamide • bendamustine • fludarabine IV
    A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors (PBC039) (NCT05396300)
    Phase 1
    Weijia Fang, MD
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    05/25/2022
    Primary completion :
    06/30/2024
    Completion :
    12/31/2025
    CEACAM5
    |
    CEACAM5 expression • CEACAM5 positive
    |
    cyclophosphamide • fludarabine IV • C-13-60
    Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies (NCT04959175)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/23/2021
    Primary completion :
    04/27/2027
    Completion :
    04/30/2027
    EGFR • IGH
    |
    cyclophosphamide • sirolimus • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous
    CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (NCT04375631)
    Phase 1
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/03/2020
    Primary completion :
    02/28/2027
    Completion :
    03/17/2027
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    cytarabine • cyclophosphamide • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (NCT05470491)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    01/26/2023
    Primary completion :
    07/30/2026
    Completion :
    07/30/2027
    IGH
    |
    bortezomib • cyclophosphamide • Selzentry (maraviroc) • plerixafor
    Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (ECOG-ACRIN 5103) (NCT00433511)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    11/02/2007
    Primary completion :
    01/07/2014
    Completion :
    02/22/2025
    HER-2 • ER
    |
    Avastin (bevacizumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • cyclophosphamide intravenous
    A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (NT-175-201) (NCT05877599)
    Phase 1
    AstraZeneca
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    07/12/2023
    Primary completion :
    09/01/2028
    Completion :
    08/01/2039
    TP53 • HLA-A
    |
    TP53 mutation • HLA-A*02:01
    |
    cyclophosphamide • fludarabine IV • NT-175
    Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (NCT00740805)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    08/18/2008
    Primary completion :
    09/03/2021
    Completion :
    10/22/2025
    HER-2 • ER • PGR • BRCA1 • BRCA
    |
    HER-2 negative • BRCA mutation
    |
    doxorubicin hydrochloride • cyclophosphamide • veliparib (ABT-888) • cyclophosphamide intravenous
    CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia (NCT06777979)
    Phase 1
    St. Jude Children's Research Hospital
    Not yet recruiting
    Last update posted :
    02/20/2025
    Initiation :
    05/01/2025
    Primary completion :
    01/01/2030
    Completion :
    01/01/2031
    CD22
    |
    cyclophosphamide • fludarabine IV • mesna
    Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    05/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    BCL2 • BCL6 • CD4
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous
    Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma (NCT01005745)
    Phase N/A
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/20/2009
    Primary completion :
    01/31/2014
    Completion :
    03/01/2025
    IFNG
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1) (NCT06091254)
    Phase 3
    Regeneron Pharmaceuticals
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/12/2023
    Primary completion :
    04/04/2029
    Completion :
    04/04/2029
    CD20
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • Ordspono (odronextamab)
    Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (NCT06172296)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    04/19/2024
    Primary completion :
    12/31/2029
    Completion :
    12/31/2029
    ALK • TERT • MYCN
    |
    cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane
    Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (NCT05554939)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/11/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    BCL2 • CCND1 • BCL6
    |
    CD19 positive • Chr t(11;14)
    |
    cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)
    Safety and Efficacy of OBX-115 in Advanced Solid Tumors (Agni-01) (NCT06060613)
    Phase 1/2
    Obsidian Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/25/2023
    Primary completion :
    10/30/2025
    Completion :
    10/30/2027
    PD-L1 • BRAF • PD-1
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • OBX-115
    Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (NCT04530565)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    01/25/2021
    Primary completion :
    07/01/2028
    Completion :
    07/01/2028
    ABL1 • BCR
    |
    ABL1 T315I
    |
    dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • dexamethasone • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection
    CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma (NCT06834529)
    Phase 1/2
    Affiliated Hospital to Academy of Military Medi...
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    01/20/2025
    Primary completion :
    01/31/2027
    Completion :
    01/31/2027
    CD22
    |
    cyclophosphamide • fludarabine IV
    Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (P30CA033572) (NCT03113500)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    05/25/2017
    Primary completion :
    07/16/2021
    Completion :
    08/12/2025
    ALK • TNFRSF8
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • daunorubicin • cyclophosphamide intravenous
    Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma (A051902) (NCT04803201)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    10/08/2021
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME
    |
    TNFRSF8 expression
    |
    doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous
    A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma (ARST2031) (NCT04994132)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    09/14/2021
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    FOXO1
    |
    cyclophosphamide • vincristine • dactinomycin • Navelbine oral (vinorelbine tartrate oral)
    An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (SKYGLO) (NCT06047080)
    Phase 3
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    09/18/2023
    Primary completion :
    06/01/2026
    Completion :
    02/28/2029
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04665765)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    01/18/2021
    Primary completion :
    07/26/2022
    Completion :
    07/08/2025
    CD20
    |
    carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. (NCT00390793)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/17/2025
    Initiation :
    09/28/2006
    Primary completion :
    02/02/2024
    Completion :
    02/02/2024
    ABL1 • BCR
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • prednisone • daunorubicin • Starasid (cytarabine ocfosfate)
    A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants with Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer) (NCT05415215)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    07/05/2022
    Primary completion :
    11/20/2024
    Completion :
    12/31/2025
    HER-2
    |
    HER-2 amplification • EGFR positive
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (NCT05862324)
    Phase 1/2
    Triumvira Immunologics, Inc.
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    08/23/2023
    Primary completion :
    08/01/2027
    Completion :
    08/01/2027
    EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA
    |
    EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2
    FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT06609928)
    Phase 1
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    03/12/2025
    Primary completion :
    10/01/2027
    Completion :
    10/01/2042
    FOLR1
    |
    cyclophosphamide • fludarabine IV